ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
MHRA approves Opdivo plus Yervoy for unresectable malignant pleural mesothelioma
August 06, 2021The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bristol Myers Squibb's (BMS) Opdivo (nivolumab) plus Yervoy (ipilimumab) combination for the first-line treatment of adult patients with unresectable malignant pleural ... -
EC Approval for Opdivo Plus Yervoy as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
June 04, 2021Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adults with unresectable malignant pleural mesothelioma (MPM). -
3SBIO makes investment in MPM's $100M Oncology Innovations Fund and donation to Dana-Farber cancer research
March 01, 2020The collaboration of INV and IRF is a unique, first of its kind, impact investing collaboration.
Pharma Sources Insight January 2025
